# Lipoproteins and Cardiovascular Health

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the efficacy and safety of cholesterol-lowering treatments, particularly statins, in the prevention and management of cardiovascular diseases. It includes meta-analyses, clinical trials, guidelines, and genetic studies related to LDL cholesterol, atherosclerotic cardiovascular risk, hypercholesterolemia, and the role of C-reactive protein. The cluster also explores the impact of statins on various patient populations and their pleiotropic effects. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10394 |
| Works | 468 |

## Topic papers all

Showing 15 of 468.

- [Diagnosis and Management of the Metabolic Syndrome](https://scholariq.org/papers/diagnosis-and-management-of-the-metabolic-syndrome/)
- [Prediction of Coronary Heart Disease Using Risk Factor Categories](https://scholariq.org/papers/prediction-of-coronary-heart-disease-using-risk-factor-categories/)
- [Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association](https://scholariq.org/papers/heart-disease-and-stroke-statistics-2020-update-a-report-from-the-american-heart/)
- [2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>](https://scholariq.org/papers/2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias-i-lipid/)
- [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR)](https://scholariq.org/papers/european-guidelines-on-cardiovascular-disease-prevention-in-clinical-practice-5/)
- [Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)](https://scholariq.org/papers/randomised-trial-of-cholesterol-lowering-in-4444-patients-with-coronary-heart/)
- [Heart disease and stroke statistics--2015 update: a report from the American Heart Association.](https://scholariq.org/papers/heart-disease-and-stroke-statistics-2015-update-a-report-from-the-american-heart/)
- [General Cardiovascular Risk Profile for Use in Primary Care](https://scholariq.org/papers/general-cardiovascular-risk-profile-for-use-in-primary-care/)
- [The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels](https://scholariq.org/papers/the-effect-of-pravastatin-on-coronary-events-after-myocardial-infarction-in/)
- [Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia](https://scholariq.org/papers/prevention-of-coronary-heart-disease-with-pravastatin-in-men-with/)
- [2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults](https://scholariq.org/papers/2013-acc-aha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce/)
- [2016 European Guidelines on cardiovascular disease prevention in clinical practice](https://scholariq.org/papers/2016-european-guidelines-on-cardiovascular-disease-prevention-in-clinical/)
- [2021 ESC Guidelines on cardiovascular disease prevention in clinical practice](https://scholariq.org/papers/2021-esc-guidelines-on-cardiovascular-disease-prevention-in-clinical-practice/)
- [2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines](https://scholariq.org/papers/2018-aha-acc-aacvpr-aapa-abc-acpm-ada-ags-apha-aspc-nla-pcna-guideline-on-the/)
- [Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease](https://scholariq.org/papers/evolocumab-and-clinical-outcomes-in-patients-with-cardiovascular-disease/)

## Topic primary papers

Showing 15 of 247.

- [2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>](https://scholariq.org/papers/2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias-i-lipid/)
- [Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)](https://scholariq.org/papers/randomised-trial-of-cholesterol-lowering-in-4444-patients-with-coronary-heart/)
- [General Cardiovascular Risk Profile for Use in Primary Care](https://scholariq.org/papers/general-cardiovascular-risk-profile-for-use-in-primary-care/)
- [The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels](https://scholariq.org/papers/the-effect-of-pravastatin-on-coronary-events-after-myocardial-infarction-in/)
- [Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia](https://scholariq.org/papers/prevention-of-coronary-heart-disease-with-pravastatin-in-men-with/)
- [2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults](https://scholariq.org/papers/2013-acc-aha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce/)
- [2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines](https://scholariq.org/papers/2018-aha-acc-aacvpr-aapa-abc-acpm-ada-ags-apha-aspc-nla-pcna-guideline-on-the/)
- [Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease](https://scholariq.org/papers/evolocumab-and-clinical-outcomes-in-patients-with-cardiovascular-disease/)
- [Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes](https://scholariq.org/papers/intensive-versus-moderate-lipid-lowering-with-statins-after-acute-coronary/)
- [2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk](https://scholariq.org/papers/2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias-lipid-modification/)
- [Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes](https://scholariq.org/papers/ezetimibe-added-to-statin-therapy-after-acute-coronary-syndromes/)
- [2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults](https://scholariq.org/papers/2013-acc-aha-guideline-on-the-treatment-of-blood-cholesterol-to-reduce-2/)
- [Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial](https://scholariq.org/papers/primary-prevention-of-cardiovascular-disease-with-atorvastatin-in-type-2/)
- [Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial](https://scholariq.org/papers/prevention-of-coronary-and-stroke-events-with-atorvastatin-in-hypertensive/)
- [Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome](https://scholariq.org/papers/alirocumab-and-cardiovascular-outcomes-after-acute-coronary-syndrome/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.